...million in upfront and near-term payments, Norwegian biotech Vaccibody...
...to VB10.NEO, a personalized DNA-based neoantigen vaccine. Vaccibody...
...million in milestones plus tiered, low double-digit royalties.Vaccibody...

...added three members to its Entrepreneur-in-Residence program: Martin Bonde, who stepped down as CEO of Vaccibody A/S...

...Cancer (SITC) meeting in National Harbor, Md. Vaccibody's neoantigen cancer vaccine leads to 50% ORR Vaccibody A/S...
...The preliminary data also showed the personalized neoantigen cancer vaccine was well tolerated. This half, Vaccibody...
...Writer Opdivo (Brand), ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Nektar Therapeutics Vaccibody A/S Celyad...

...was COO at Tobira Therapeutics Inc. , now part of Allergan plc (NYSE:AGN). Vaccine company Vaccibody A/S...

...Adenoviral DNA vector encoding over 100 neoantigens Cancer Preclinical Unknown Life Sciences Partners; Versant Ventures Vaccibody A/S...

...Vaccine company Vaccibody A/S (Oslo, Norway) raised NOK220 million ($26 million) through the sale of 880,000 shares...
...sale of 880,000 shares at NOK250 in a private placement with new and existing investors. Vaccibody...
...malignancies. Capital has become increasingly available for start-ups in Scandinavia (see BioCentury, Aug. 22) . Chris Lieu VB10.16 Vaccibody A/S...

...$26 million) in a venture round with new and existing investors. Vaccibody A/S , Oslo, Norway Alicia Parker Vaccibody A/S...

...14 evaluable patients, 12 patients (86%) achieved “strong induction” of HPV16-specific T cell immune responses. Vaccibody...
...patients (75%) regressed to CIN grade 1 or no disease at 6 months of follow-up. Vaccibody...
...of the trial to the expansion Phase IIa portion, which will enroll 15-20 additional patients. Vaccibody A/S...

...ventures business from other industries but certainly weren't biotech specialists," said Martin Bonde, CEO of Vaccibody A/S...
...Rock or a Versant that does things in a big way from the beginning," said Vaccibody's...
...York, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Tekes, Helsinki, Finland Umeå University , Umeå, Sweden Vaccibody A/S...

...selected from the first part in 15-20 patients with CIN grade 2 or 3 lesions. Vaccibody A/S...